339 related articles for article (PubMed ID: 28960945)
1. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
2. Akt Pathway Inhibitors.
Uko NE; Güner OF; Matesic DF; Bowen JP
Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
[TBL] [Abstract][Full Text] [Related]
3. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
4. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
[TBL] [Abstract][Full Text] [Related]
5. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
6. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer.
Wang J; Xu X; Wang T; Guo Q; Dai X; Guo H; Zhang W; Cheng S; Chen X; Ding L
Eur J Pharmacol; 2021 Apr; 896():173879. PubMed ID: 33515539
[TBL] [Abstract][Full Text] [Related]
7. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
[TBL] [Abstract][Full Text] [Related]
8. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
[TBL] [Abstract][Full Text] [Related]
9. TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
Yuan BZ; Chapman J; Ding M; Wang J; Jiang B; Rojanasakul Y; Reynolds SH
BMC Cancer; 2013 Mar; 13():140. PubMed ID: 23517112
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
[TBL] [Abstract][Full Text] [Related]
11. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
[TBL] [Abstract][Full Text] [Related]
12. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.
Pinton G; Manente AG; Angeli G; Mutti L; Moro L
PLoS One; 2012; 7(5):e36856. PubMed ID: 22590625
[TBL] [Abstract][Full Text] [Related]
13. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R
Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249
[TBL] [Abstract][Full Text] [Related]
15. Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.
Kaku Y; Nagaya H; Tsuchiya A; Kanno T; Gotoh A; Tanaka A; Shimizu T; Nakao S; Tabata C; Nakano T; Nishizaki T
Cancer Sci; 2014 Jul; 105(7):883-9. PubMed ID: 24754309
[TBL] [Abstract][Full Text] [Related]
16. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
17. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
18. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Giovannetti E; Zucali PA; Assaraf YG; Leon LG; Smid K; Alecci C; Giancola F; Destro A; Gianoncelli L; Lorenzi E; Roncalli M; Santoro A; Peters GJ
Br J Cancer; 2011 Nov; 105(10):1542-53. PubMed ID: 21970874
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Miyoshi S; Hamada H; Hamaguchi N; Kato A; Katayama H; Irifune K; Ito R; Miyazaki T; Okura T; Higaki J
Int J Oncol; 2012 Aug; 41(2):449-56. PubMed ID: 22580933
[TBL] [Abstract][Full Text] [Related]
20. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]